The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.
Author
Patient Prefer Adherence. 2020 May 18;14:829-838. doi: 10.2147/PPA.S221897.eCollection 2020.
Glen S Hazlewood 1 2 3, Deborah A Marshall 1 2 3, Claire E H Barber 1 2 3, Linda C Li 3, Cheryl Barnabe 1 2 3, Vivian Bykerk 4 5, Peter Tugwell 6, Pauline M Hull 7, Nick Bansback 3 8
Author Information
1 Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.
2 McCaig Institute of Bone and Joint Health, University of Calgary, Calgary, Canada.
3 Arthritis Research Canada, Vancouver, BC, Canada.
4 Weill Cornell Medical College, Cornell University, New York, NY, USA.
5 Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
6 Department of Medicine, Department of Epidemiology and Community Medicine, Canada Research Chair, University of Ottawa, Institute of Population Health, Ottawa, Canada.
7 University of Calgary, Calgary, Canada.
8 Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, Canada.
Free PMC article
Abstract
Purpose: To evaluate, in a proof-of-concept study, a decision aid that incorporates hypothetical choices in the form of a discrete-choice experiment (DCE), to help patients with early rheumatoid arthritis (RA) understand their values and nudge them towards a value-centric decision between methotrexate and triple therapy (a combination of methotrexate, sulphasalazine and hydroxychloroquine).
Patients and methods: In the decision aid, patients completed a series of 6 DCE choice tasks. Based on the patient's pattern of responses, we calculated his/her probability of choosing each treatment, using data from a prior DCE. Following pilot testing, we conducted a cross-sectional study to determine the agreement between the predicted and final stated preference, as a measure of value concordance. Secondary outcomes including time to completion and usability were also evaluated.
Results: Pilot testing was completed with 10 patients and adjustments were made. We then recruited 29 patients to complete the survey: median age 57, 55% female. The patients were all taking treatment and had well-controlled disease. The predicted treatment agreed with the final treatment chosen by the patient 21/29 times (72%), similar to the expected agreement from the mean of the predicted probabilities (68%). Triple therapy was the